AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31828590
Drug: Intraarticular corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular corticosteroid injection (IACSI)
Trial: 31828590
Drug: Intraarticular corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular corticosteroid injection (IACSI) + Genicular nerve block (GNB)
Trial: 30934041
Drug: Narrow-diameter titanium-zirconium
RxNorm normalized name: zirconium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-diameter titanium-zirconium (Ti-Zr) alloy implants
Trial: 30934041
Drug: Standard-diameter implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-diameter implants
Trial: 30934041
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (narrow-diameter and standard-diameter implants)
Trial: 21574983
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections matching active treatment
Trial: 17352847
Drug: Adjunctive T3
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive T3
Trial: 17241714
Drug: JE‐PIV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE‐PIV vaccine administered in either two or three intramuscular (IM) doses (6.0 or 12.0 mcg each)
Trial: 25686143
Drug: RIN-150 (rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIN-150 (rifampicin 150 mg and isoniazid 75 mg)
Trial: 23727264
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg OCA
Trial: 23727264
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg OCA
Trial: 21078196
Drug: Family-focused cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused cognitive-behavioral therapy (CBT)
Trial: 21078196
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control (no therapy)
Trial: 18822906
Drug: Artificial menstrual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial menstrual cycle therapy (Control)
Trial: 14519634
Drug: Adjuvant 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant 5-fluorouracil (5-FU) therapy
Trial: 10768906
Drug: Intracoronary dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary dipyridamole (0.5 mg/kg bodyweight)
Trial: 10768906
Drug: Conventional pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pretreatment (heparin 15,000 IU and aspirin 500 mg intravenously)
Trial: 1358922
Drug: terazosin (2‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terazosin (2‐4 mg/day for 4 weeks)
Trial: 4044461
Drug: Macrodantin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrodantin (100 mg at night)
Trial: 4044461
Drug: Trimethoprim (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (100 mg at night)
Trial: 30636727
Drug: 4-week home-based
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week home-based treatment program including orthotics and strengthening exercises
Trial: 29498348
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml blood orange juice providing 50 mg anthocyanins/d
Trial: 29498348
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml blonde orange juice without anthocyanins
Trial: 27561137
Drug: Public health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Public health dose (16 kcal/kg/wk) of exercise for 12 weeks
Trial: 27561137
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (4 kcal/kg/wk) of exercise for 12 weeks
Trial: 24041737
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume polyethylene glycol (50 mL/kg, up to 2Lt/die) (Group B)
Trial: 24041737
Drug: Low volume
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume polyethylene glycol (25 mL/kg, up to 1Lt/die) (Group C)
Trial: 24041737
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL (376 mg) of oral simethicone (Group D)
Trial: 24041737
Drug: 25 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL/kg (up to 1Lt/die) of polyethylene glycol solution plus 20 mL (376 mg) of oral simethicone (Group E)
Trial: 22513502
Drug: Tadalafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (10 to 20 mg, increased based on effects and adverse reactions)
Trial: 20551183
Drug: Antiangiogenic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic drugs (sorafenib [n = 10], sunitinib [n = 22])
Trial: 18948239
Drug: Amiodarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone treatment (Group A)
Trial: 18948239
Drug: No amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No amiodarone treatment (Group B)
Trial: 11895046
Drug: P. ginseng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. ginseng 200 mg/d
Trial: 6183864
Drug: Oral methoxsalen
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methoxsalen
Trial: 6183864
Drug: Topical trioxsalen
RxNorm normalized name: Trioxsalen
DrugBank: Trioxsalen (DB04571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical trioxsalen
Trial: 31725473
Drug: Risperidone plus
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone plus Propentofylline (300 mg/d)
Trial: 22223180
Drug: Rilonacept (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (320 mg loading dose followed by 160 mg weekly)
Trial: 17189087
Drug: Postural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postural therapy
Trial: 12170040
Drug: Intravenous parecoxib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous parecoxib, 20 mg
Trial: 12170040
Drug: Intravenous parecoxib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous parecoxib, 40 mg
Trial: 10094236
Drug: Antidepressants (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (at follow-up)
Trial: 2378770
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg kg‐1 with adrenaline 5 micrograms ml‐1
Trial: 2378770
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg kg‐1 without adrenaline
Trial: 796476
Drug: Aspartame (2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (2.7 g/day)
Trial: 21718738
Drug: dTpa vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa vaccine (Boostrix(®))
Trial: 18637602
Drug: Combined intrathecal
RxNorm normalized name: Intrathecal Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intrathecal and epidural magnesium (50 mg of 5% Mg and 2% Mg at a rate of 100 mg/hr)
Trial: 18637602
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg of Bupivacaine 0.5% plus 25 microg of Fentanyl plus 50 mg of 5% Mg
Trial: 18637602
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg of Bupivacaine 0.5% plus 25 microg of Fentanyl plus 0.9% NaCl solution
Trial: 17160911
Drug: Fenofibrate-statin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate-statin combination therapy
Trial: 12585144
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and GBYL (Group B)
Trial: 12585144
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and GBYL plus moxibustion (Group C)
Trial: 12585144
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and placebo (Group A)
Trial: 9730668
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment, 0.2 IU/kg/body weight daily for 3 years
Trial: 9730668
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group 2) with 1-year observation followed by 3 years of GH treatment, 0.2 IU/kg/body weight daily
Trial: 9730668
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (GH treatment)
Trial: 127655
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus RAJI immunotherapy
Trial: 23941313
Drug: Bupropion (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (active treatment)
Trial: 23941313
Drug: Cognitive-behavioral smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral smoking cessation treatment (CBT)
Trial: 22772870
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg
Trial: 14565994
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training combined with GH administration
Trial: 11370690
Drug: Raspberry leaf
RxNorm normalized name: Raspberry leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raspberry leaf tablets (2 x 1.2 g per day)
Trial: 9234828
Drug: Diltiazem 240
RxNorm normalized name: diltiazem 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 240 mg + Lisinopril 10 mg
Trial: 9234828
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg + Lisinopril 10 mg
Trial: 27113362
Drug: Tailored patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored patient education intervention (nurse-conducted medication counselling, information booklet, video, website, text message reminders)
Trial: 22492424
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) 75 U/1.5 mL
Trial: 22492424
Drug: Saline (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1.5 mL)
Trial: 15377480
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) administration after transplantation
Trial: 11486241
Drug: Uric acid,
RxNorm normalized name: SULFURIC ACID,TECHNICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid, 1,000 mg
Trial: 11486241
Drug: Vitamin C,
RxNorm normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C, 1,000 mg
Trial: 9658668
Drug: dotarizine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dotarizine (50 mg b.i.d.)
Trial: 9658668
Drug: cinnarizine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinnarizine (75 mg b.i.d.)
Trial: 3394909
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline
Trial: 31613050
Drug: Permethrin 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 2.5% with tea tree oil gel
Trial: 28797867
Drug: Compression group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression group (CG) with circular-knit sleeves in compression class I (15-21 mm Hg) for daily wearing (n=23)
Trial: 8256468
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy (600 mg of D‐alpha tocopherol per day, 200 micrograms of selenium, and 12 mg of zinc)
Trial: 23514246
Drug: Primary radiotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary radiotherapy (RT) ± chemotherapy
Trial: 16963850
Drug: Anecortave acetate
RxNorm normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anecortave acetate 30 mg
Trial: 16963850
Drug: Anecortave acetate
RxNorm normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anecortave acetate 3 mg
Trial: 15072030
Drug: Levofloxacin 300
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 300 mg orally once daily (LEV group)
Trial: 15072030
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid 625 mg three times a day (COA group)
Trial: 9626225
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m2 intravenously (i.v.) over 30 minutes daily for 5 days repeated every 21 days (arm A)
Trial: 9626225
Drug: Topotecan 1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.75 mg/m2 as a 24-hour infusion once a week for 4 weeks repeated every 6 weeks (arm B)
Trial: 14980942
Drug: Combined spinal-epidural
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spinal-epidural anesthesia (CSE) with intrathecal hyperbaric 0.5% bupivacaine 5 mg and fentanyl 10 microg, followed by 0.9% saline 6.0 mL through the epidural catheter 5 min thereafter
Trial: 14980942
Drug: Single-shot spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot spinal anesthesia with hyperbaric 0.5% bupivacaine 9 mg and fentanyl 10 microg
Trial: 9619732
Drug: High-dose ara-C/daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ara-C/daunorubicin (HDara-C/DNR) after idarubicin induction
Trial: 9619732
Drug: High-dose ara-C/daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ara-C/daunorubicin (HDara-C/DNR) after daunorubicin induction
Trial: 7633693
Drug: Nasal immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal immunotherapy (LNIT) with Parietaria
Trial: 2675377
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg x 2/day for two weeks, then 10 mg x 2/day for two months)
Trial: 2675377
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg/day for two months)
Trial: 359017
Drug: Nordiazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordiazepam (5 mg)
Trial: 42628
Drug: Nordiazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordiazepam (10 mg)
Trial: 359017
Drug: Oxazepam (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (45 mg)
Trial: 359017
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg) morning ingestion
Trial: 359017
Drug: Temazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (20 mg) morning ingestion
Trial: 359017
Drug: Oxazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (30 mg) morning ingestion
Trial: 359017
Drug: Nordiazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordiazepam (10 mg) morning ingestion
Trial: 359017
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg) choice response time test
Trial: 359017
Drug: Temazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (20 mg) choice response time test
Trial: 25833972
Drug: WinFood-Lite (WF-L)
RxNorm normalized name: Lite 'N Foamy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WinFood-Lite (WF-L)
Trial: 19288533
Drug: Castor oil
RxNorm normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Castor oil capsule 0.9 mL, thrice daily for 4 weeks
Trial: 19288533
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium capsule 50 mg, thrice daily for 4 weeks
Trial: 14748914
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor antagonism
Trial: 11395029
Drug: Fortified fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified fat spread (25 g/day providing 2.5 g of plant sterols)
Trial: 9232297
Drug: PCEA using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA using meperidine with background infusion (group Pi)
Trial: 9232297
Drug: PCEA using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA using meperidine without background infusion (group Po)
Trial: 8125422
Drug: Captopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (ACE inhibitor), started after the first day but within 72 hours of onset of chest pain
Trial: 7836197
Drug: Aminophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (5 mg/kg)
Trial: 22768459
Drug: Placebo (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5% dextrose water for injection, 5 cc/kg)
Trial: 16510384
Drug: Topical Symphytum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Symphytum product Traumaplant (10% active ingredient)
Trial: 16510384
Drug: 1% reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% reference product (2.5 g of fresh comfrey herb in 100 g of cream)
Trial: 8848206
Drug: Bromocriptine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (up to 60 mg/d)
Trial: 2081142
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 120 mg (V120 SR) given twice daily (bid)
Trial: 2081142
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 240 mg (V240 SR) given once daily (od)
Trial: 35414
Drug: Clonidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (2 X 0.025 mg/24 hours - 0.075 mg/24 hours, increased if necessary at intervals of two weeks)
Trial: 24092827
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.05 mg/d)
Trial: 11096165
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg)
Trial: 21440672
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bisacodyl once daily for 4 weeks
Trial: 19146605
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Arctium lappa fruit extract-containing formulation for 12 weeks
Trial: 19146605
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Arctium lappa fruit extract-containing formulation for 4 weeks
Trial: 9167505
Drug: Sertindole 20
RxNorm normalized name: sertindole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole 20 mg/day
Trial: 8935813
Drug: Sertindole (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole (various doses)
Trial: 3159639
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine alone (Group I)
Trial: 3159639
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine + HBIG at birth (Group II)
Trial: 3159639
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine + HBIG at birth and again at one month (Group III)
Trial: 22734376
Drug: Acupuncture-rehabilitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture-rehabilitation group (routine rehabilitation therapy combined with electroacupuncture therapy)
Trial: 12058428
Drug: Amrinone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (5 mcg.kg‐1.min‐1) administered after coronary artery anastomosis (A 1 group: 11 cases)
Trial: 12058428
Drug: Amrinone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (5 mcg.kg‐1.min‐1) administered after induction of anesthesia (A 2 group: 13 cases)
Trial: 6173522
Drug: Captopril 150
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril 150 mg/day
Trial: 8603632
Drug: Felbamate (FBM)
RxNorm normalized name: Felbamate
DrugBank: Felbamate (DB00949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felbamate (FBM) at doses of 1,200, 2,400, 3,000, or 3,600 mg/day (n = 2-4 per group)
Trial: 1936112
Drug: 54Fe-labelled iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54Fe-labelled iron preparation (150 mg Fe2+ daily)
Trial: 1936112
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available iron preparation (160 mg Fe2+ daily)